Gimeracil/oteracil/tegafur - Taiho Pharmaceutical

Drug Profile

Gimeracil/oteracil/tegafur - Taiho Pharmaceutical

Alternative Names: BMS-247616; S-1; Tegafur/gimeracil/oteracil; Teysuno; TS-1; TS-ONE

Latest Information Update: 28 Jun 2018

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Taiho Pharmaceutical
  • Developer Nordic Group; Shandong New age Pharmaceutical; Taiho Pharmaceutical; TTY Biopharm
  • Class Antineoplastics; Pyridines; Pyrimidinones; Small molecules; Triazines
  • Mechanism of Action Thymidylate synthase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Gastric cancer
  • New Molecular Entity No

Highest Development Phases

  • Marketed Biliary cancer; Breast cancer; Colorectal cancer; Gastric cancer; Head and neck cancer; Non-small cell lung cancer; Pancreatic cancer
  • Phase III Cervical cancer; Hepatocellular carcinoma; Uterine cancer
  • Phase II Oesophageal cancer; Renal cancer
  • No development reported Prostate cancer

Most Recent Events

  • 28 Jun 2018 No recent reports of development identified for phase-I development in Gastric-cancer(Combination therapy, Metastatic disease) in China (PO, Capsule)
  • 28 Jun 2018 No recent reports of development identified for phase-I development in Pancreatic-cancer(First-line therapy, Metastatic disease) in Taiwan (PO, Capsule)
  • 01 Jun 2018 Efficacy and adverse events data of a phase I trial in Gastrointestinal cancer presented at the 54th Annual Meeting of the American Society of Clinical Oncology (ASCO-2018)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top